Cargando…
Regulation of temozolomide resistance in glioma cells via the RIP2/NF‐κB/MGMT pathway
BACKGROUND: Temozolomide (TMZ) is a first‐line chemotherapy drug for the treatment of malignant glioma and resistance to it poses a major challenge. Receptor‐interacting protein 2 (RIP2) is associated with the malignant character of cancer cells. However, it remains unclear whether RIP2 is involved...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025621/ https://www.ncbi.nlm.nih.gov/pubmed/33460245 http://dx.doi.org/10.1111/cns.13591 |